![David Lovejoy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 1 042 $ op 30-06-2026
David A. Lovejoy was the founder of Protagenic Therapeutics, Inc. which was founded in 1994, where he held the title of Chief Scientific Officer.
He also held the position of Principal at the University of Toronto.
Dr. Lovejoy earned a doctorate degree from the University of Victoria.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-11-2025 | 2.657 ( 0,14% ) | 1 042 $ | 30-06-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| PROTAGENIC THERAPEUTICS, INC. | Oprichter | - |
Protagenic Therapeutics, Inc. /Old/
 Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders | Hoofd Techniek/Wetenschap/O&O | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 4 |
|---|---|
Protagenic Therapeutics, Inc. /Old/
Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders | Health Technology |
University of Toronto
University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Victoria
 University of Victoria Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Protagenic Therapeutics, Inc.
 Protagenic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates biopharmaceutical company that engages in discovery and development of therapeutics to treat stress-related neuropsychiatric & mood disorders | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
Kies MarketScreener 
